Los Angeles Capital Management LLC Lowers Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Los Angeles Capital Management LLC reduced its holdings in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 17.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 28,032 shares of the company’s stock after selling 5,900 shares during the period. Los Angeles Capital Management LLC owned about 0.07% of Entrada Therapeutics worth $485,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. US Bancorp DE acquired a new position in shares of Entrada Therapeutics in the third quarter worth $42,000. China Universal Asset Management Co. Ltd. acquired a new position in Entrada Therapeutics during the 4th quarter worth $137,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Entrada Therapeutics by 34.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock worth $226,000 after purchasing an additional 3,644 shares during the period. SG Americas Securities LLC increased its holdings in Entrada Therapeutics by 44.0% during the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock worth $243,000 after purchasing an additional 4,291 shares during the period. Finally, Public Employees Retirement System of Ohio raised its position in Entrada Therapeutics by 89.1% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 16,259 shares of the company’s stock valued at $260,000 after purchasing an additional 7,659 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Oppenheimer boosted their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Tuesday, February 25th. Roth Mkm began coverage on shares of Entrada Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $29.00 price objective on the stock. Finally, Roth Capital raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $20.77, for a total transaction of $476,359.95. Following the transaction, the insider now owns 4,402,849 shares of the company’s stock, valued at $91,447,173.73. The trade was a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 7.59% of the stock is currently owned by insiders.

Entrada Therapeutics Stock Down 5.1 %

TRDA stock opened at $11.33 on Tuesday. The business has a 50 day moving average price of $14.18 and a 200 day moving average price of $16.22. The stock has a market cap of $423.97 million, a price-to-earnings ratio of 7.13 and a beta of -0.17. Entrada Therapeutics, Inc. has a fifty-two week low of $11.28 and a fifty-two week high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.69. The business had revenue of $12.25 million during the quarter, compared to the consensus estimate of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. As a group, sell-side analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.